Halle Berry on Menopause: What She's Said, What She Takes, and What It Means for You

What Halle Berry Has Actually Said About Menopause

Berry's public statements on menopause are specific, consistent, and span more than five years of interviews and social media posts. She is not vague about her experience.

In a widely shared 2023 appearance at the Equity in Menopause Care briefing on Capitol Hill, Berry spoke alongside physicians and legislators to call for greater research funding and clinical education on menopause. She described menopause as "the most significant thing that happens to a woman's body, arguably after childbirth," and said the silence around it had left her "completely blindsided." That event was documented by multiple press outlets including People, Vogue, and Variety, and C-SPAN archived portions of the session.

Berry has also spoken on several podcasts and in magazine profiles about the moment she first experienced symptoms. She told a reporter that she initially believed she had a sexually transmitted infection because her primary care physician at the time did not raise menopause as a possibility when she described her symptoms. She was in her late 30s. That misdiagnosis story is clinically plausible: perimenopause can begin as early as the mid-30s, and genital symptoms such as vaginal dryness or irritation are frequently attributed to infection before hormonal causes are considered.

The Respin Platform

Berry co-founded Respin, a digital health and lifestyle platform, with the stated goal of giving midlife women access to credible health information. The platform has published content on menopause symptom management, hormone therapy, nutrition, and fitness for women over 40. Berry has described it in interviews as a response to her own experience of finding "nothing designed for women like me" when she searched for answers about her symptoms.

Respin is a commercial product, and WomanRx notes this context: content produced by a celebrity-founded platform should be evaluated alongside peer-reviewed clinical sources. Berry's consistent public advocacy has contributed to measurable increases in Google search volume for "menopause" and "HRT" among women 35 and older around periods when she has made major statements, a pattern also observed after other high-profile menopause disclosures from figures such as Michelle Obama and Naomi Watts.

Her Specific Statements on Hormone Therapy

Berry has stated in interviews that she uses hormone replacement therapy. In a 2023 interview with Women's Health magazine, she confirmed she takes estrogen and progesterone and described the change as significant for her energy, sleep, and overall sense of herself. She has not, in verified public statements, named specific drug brands or doses. Any article attributing specific product names to her without a direct quoted source should be read with skepticism.

She has also said she works closely with a physician who specializes in menopause, and she has described the process of finding that physician as difficult and time-consuming. This tracks with documented gaps in menopause training: a 2019 survey published in Menopause found that fewer than 20% of ob-gyn residency programs provided formal menopause education, leaving many clinicians underprepared to counsel patients on midlife hormonal transitions.

A clinical note from WomanRx: Berry's public account follows a pattern our clinicians hear regularly from patients. Women in their late 30s and early 40s presenting with irregular cycles, sleep disruption, mood changes, joint pain, or genital symptoms are often evaluated for thyroid disease, depression, or infection before perimenopause is considered. This is a systemic diagnostic gap, not an individual clinician failure, and it reflects how little menopause has been integrated into routine women's preventive care.

The Clinical Picture Behind Her Story: Perimenopause Across Life Stages

Berry's experience of symptoms beginning in her late 30s is not unusual, though it sits toward the earlier end of the typical range.

Reproductive Years and Early Perimenopause

Perimenopause, defined as the hormonal transition leading to the final menstrual period, typically begins in a woman's mid-to-late 40s, but the SWAN (Study of Women's Health Across the Nation) cohort documented that some women begin experiencing irregular cycles and vasomotor symptoms as early as their late 30s. Early menopause before age 40 affects approximately 1% of women and is classified as primary ovarian insufficiency (POI), a distinct condition with its own hormone therapy protocols.

For women in their late 30s and early 40s who are still having periods but notice changes in cycle length, heavier or lighter bleeding, new onset insomnia, or temperature dysregulation, perimenopause may be the explanation even when a pregnancy test is negative and thyroid function is normal.

Postmenopause

Natural menopause is defined retrospectively, after 12 consecutive months without a menstrual period. The average age at natural menopause in the United States is 51.4 years, though race, smoking history, family history, and body composition all influence timing. Once postmenopause is established, many women experience persistent vasomotor symptoms, genitourinary syndrome of menopause (GSM), accelerated bone loss, and shifts in cardiovascular risk profile.

Berry, born in 1966, would have reached this stage in her early to mid 50s if her perimenopause began in her late 30s, which is consistent with her public timeline.

Women With PCOS, Thyroid Conditions, or Prior Fertility Treatment

Women with polycystic ovary syndrome (PCOS) may have irregular cycles throughout their reproductive years, making it harder to identify when perimenopause begins, because the hallmark of cycle irregularity is already present at baseline. Women with thyroid disease face a similar diagnostic challenge, since hypothyroidism and perimenopause share symptoms including fatigue, weight change, mood shifts, and menstrual irregularity. Berry has not publicly disclosed either condition, but these overlaps are worth naming because they affect a large share of women who may see themselves in her story.

What the Evidence Says About Hormone Therapy for Menopause

Berry has said HRT helped her. The clinical evidence supports that position for the right candidates, with important nuances.

Efficacy for Vasomotor Symptoms

Estrogen therapy remains the most effective available treatment for moderate to severe vasomotor symptoms (hot flashes and night sweats). The 2023 position statement from The Menopause Society states that hormone therapy is appropriate for healthy women under 60 or within 10 years of menopause onset who have bothersome symptoms, provided there are no contraindications. This represents a significant shift from the overcorrection that followed the initial 2002 Women's Health Initiative (WHI) results.

The WHI Reanalysis and What It Changed

The original Women's Health Initiative trial, published in JAMA in 2002, reported increased breast cancer risk and cardiovascular events in women taking combined estrogen plus progestin, causing a sharp drop in HRT prescribing that persisted for nearly two decades. Later reanalysis made clear that the WHI population was older (average age 63) and further from menopause onset than the women most likely to be prescribed HRT today. The risk profile for women who begin hormone therapy within 10 years of menopause is substantially different from the risk seen in older women initiating therapy later.

A 2017 Cochrane review of HRT for menopausal symptoms confirmed benefits for hot flashes, sleep quality, and quality of life, with the evidence strongest for women in early menopause. For women with an intact uterus, progestogen is added to protect the endometrium, which is the context for combined estrogen-progesterone regimens of the kind Berry has described using.

Bone Health

Estrogen has a well-documented protective effect on bone density. Women lose bone at an accelerated rate in the first 3 to 5 years after menopause, and ACOG Practice Bulletin No. 141 notes that systemic hormone therapy prevents bone loss and reduces fracture risk in postmenopausal women. This is particularly relevant for women who enter menopause early, as Berry may have, given the longer duration of estrogen deficiency they face.

Cardiovascular and Metabolic Considerations

The relationship between HRT and cardiovascular risk depends heavily on age at initiation, type of hormone, route of administration, and baseline risk factors. Transdermal estrogen carries a lower risk of venous thromboembolism than oral formulations, a difference that has been documented in the E3N cohort study and matters particularly for women with elevated thrombotic risk. Women with metabolic syndrome, hypertension, or a history of migraine with aura need individualized assessment before starting any hormone therapy.

Pregnancy, Lactation, and Contraception: What Women in Perimenopause Need to Know

This section is required reading for women in their late 30s and 40s who may be in early perimenopause but have not yet reached menopause.

Perimenopause does not equal infertility. Women can and do conceive during perimenopause. Ovulation can occur unpredictably even when cycles are irregular. If you do not want to become pregnant, you need reliable contraception until you have had 12 consecutive months without a period (postmenopause).

Hormone therapy used for menopause is not contraception. Low-dose estrogen and progesterone prescribed for menopause management does not suppress ovulation reliably. Women who are perimenopausal and sexually active with a possibility of pregnancy should not rely on menopausal HRT for contraception.

Safe contraceptive options in perimenopause include:

• Low-dose combined oral contraceptives (if no contraindications such as migraine with aura, smoking over 35, or cardiovascular disease)
• Progestin-only pills or the hormonal IUD
• The copper IUD (non-hormonal, highly effective, appropriate for women who cannot use hormonal methods)

Women who become pregnant during perimenopause face higher rates of chromosomal abnormalities and pregnancy complications. Hormone therapy formulations used for menopause are not studied or indicated in pregnancy and should be discontinued if pregnancy occurs. A reproductive endocrinologist or maternal-fetal medicine specialist should be consulted for pregnancy management in women over 40.

Lactation: Standard menopause HRT is not indicated in postpartum or lactating women. The hormonal context of lactation involves elevated prolactin and suppressed estrogen; exogenous estrogen may reduce milk supply. Women who are postpartum and experiencing premature ovarian insufficiency or surgical menopause should work with a specialist to balance lactation goals with any necessary hormone support.

Who This Applies To (and Who It Does Not)

Berry's story resonates most directly with women in their late 30s through early 60s who are in perimenopause or early postmenopause. Her advocacy is particularly meaningful for Black women, who are documented by SWAN data to experience more frequent and more severe vasomotor symptoms than white women, begin perimenopause earlier on average, and have historically received less thorough menopause counseling from clinicians.

Hormone therapy may be appropriate if:

• You are under 60 or within 10 years of menopause onset
• You have moderate to severe vasomotor symptoms that affect sleep or quality of life
• You have no personal history of hormone-sensitive breast cancer, unexplained vaginal bleeding, active liver disease, or high thrombotic risk
• You have discussed the benefit-risk balance with a clinician who has reviewed your full history

Hormone therapy is not appropriate (or requires specialist review) if:

• You have a personal history of estrogen-receptor-positive breast cancer
• You have active or recent cardiovascular disease or stroke
• You have unexplained uterine bleeding
• You are pregnant or trying to conceive with IVF in a hormonally complex situation (specialist review required)
• You have migraines with aura and are considering combined estrogen-progestin (progestin-only or transdermal options may still be appropriate)

Women with PCOS, thyroid disease, a history of postpartum thyroiditis, or endometriosis need individualized counseling because these conditions interact with the hormonal changes of menopause in ways that one-size guidance cannot address.

The Evidence Gap: What We Still Don't Know

Berry's advocacy has highlighted real gaps in research and clinical practice. Women, particularly Black women, women with chronic conditions, and women who experienced early menopause, have been underrepresented in menopause clinical trials. The WHI, the largest hormone therapy trial ever conducted, enrolled predominantly white postmenopausal women with an average age of 63. Its findings cannot be cleanly extrapolated to younger women, women of color, or women beginning HRT in early perimenopause.

The SWAN study has been the most ethnically diverse longitudinal menopause cohort in the U.S., but even SWAN was not powered to answer questions about optimal HRT dosing or formulation across different racial groups. Researchers and advocates, including those working with Berry's platform, have called for federally funded trials that enroll women across the full demographic spectrum of menopause experience.

This is an area where WomanRx follows the science honestly: the data we have is real and supports HRT for many women, and the data we need for more precise, individualized guidance does not fully exist yet. Recognizing that gap is not a reason to avoid treatment. It is a reason to work with a clinician who will individualize your care rather than apply a single template.

What to Ask Your Clinician (Derived From Berry's Own Reported Experience)

Berry has described her path to good care as involving persistence, second opinions, and eventually finding a physician who specialized in menopause. Based on her documented statements and the clinical context, here are specific questions to bring to your appointment:

• "I'm having symptoms that may be perimenopause. Will you check FSH, estradiol, and TSH to help clarify the picture, even though I'm still having periods?"
• "Am I a candidate for hormone therapy, and if not, what is the specific reason in my case?"
• "What route of administration (patch, gel, oral, vaginal) would you recommend for my risk profile, and why?"
• "Do I need progestogen, and if so, which type? Is micronized progesterone an option for me?"
• "How will we monitor my response and adjust the dose?"
• "If hormone therapy isn't right for me, what non-hormonal options have the strongest evidence for my specific symptoms?"

FSH levels fluctuate significantly during perimenopause and a single normal FSH reading does not rule out perimenopause. Estradiol measured on day 2 to 3 of the cycle (if cycles are still occurring) gives more useful information. A clinician who dismisses perimenopausal symptoms solely on the basis of a single FSH within normal limits warrants a second opinion.

Journalistic Note: What Is Verified, What Is Inferred

WomanRx applies the same sourcing standards to celebrity health content that we apply to clinical articles. Here is a clear breakdown for this piece.

Verified from named sources:

• Berry confirmed HRT use in a 2023 Women's Health magazine interview
• Berry spoke at the Capitol Hill briefing on menopause equity in 2023 (archived media coverage)
• Berry co-founded Respin (company registration and press releases confirm this)
• Berry described early symptom onset and initial misdiagnosis in multiple interviews

Reasonable clinical inference, labeled as such:

• Her specific medications, doses, and prescribing clinician's name are not publicly known
• Whether she uses transdermal or oral estrogen has not been confirmed in any verified interview
• The duration of her hormone therapy use is not precisely documented

Any article that names specific drug brands or doses as Berry's regimen without a direct quoted source is speculating. We do not do that here.